Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: Huntington's disease therapies - BioElectron Technology/CHDI

Drug Profile

Research programme: Huntington's disease therapies - BioElectron Technology/CHDI

Alternative Names: Second-generation coenzyme Q10 analogues - BioElectron Technology/CHDI; Ubidecarenone analogues - BioElectron Technology/CHDI

Latest Information Update: 14 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CHDI; Edison Pharmaceuticals
  • Developer BioElectron Technology; CHDI
  • Class
  • Mechanism of Action Antioxidants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Huntington's disease

Most Recent Events

  • 01 Aug 2018 Edison Pharmaceuticals is now called BioElectron Technology
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Huntington's-disease in USA
  • 01 Aug 2006 Preclinical trials in Huntington's disease in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top